Empowered and informed customers, interested in preventive care and monitoring, side effects and scientific approach for medicine 

Aging population, Silver economy and rising baby boomer population increases the older customer base

Move from Therapeutical to Preventive choices prolongs the period of targeting the customers in pharmaceutical cycle

Growth on emerging market

Growing health awareness and want of control and monitoring of health

With convergence of IT and healthcare, new segments as e-patients arise and new approaches as gamification and 3D printing disrupt the industry

Data availability and accessibility increases the consumer data analytics power (Big data; Artificial Intelligence and Analytics, Digitisation of data)

Convergence of IT and healthcare, E-patients, Genomics, 3-D printing, Biosimilars, Nano robots, Genomics

mHealth: There is rising optimism about the potential of mobile health (mHealth) to deliver cost-effective care. As with any new technology, however, evaluation can help to ensure that mHealth achieves its potential.

Increasing focus on advanced technologies

Remote Monitoring  using technology - Wearables and tracking systems

Gamification/VR

Technology assisted services such as drug dispensing is on the rise

Increased spending on healthcare: high net worth growth, higher purchasing power and interest in higher-end medicines

Globalisation opens up new market for drug consumption and new market segments

Glocal supply chains, Green systems, IPR for compounds or synthesis techniques

Drug Pricing and Spending: Conversations on how to manage drug prices are becoming more commonplace, with a particular focus on ensuring that drug prices reflect the value of treatment.

Sustainability awareness and biodegradable ingredient requirements

More interest on chemicals used in the process of development of drug

Eco friendly ingredient  preference